These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 23760496)
1. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Pierce A; McGowan PM; Cotter M; Mullooly M; O'Donovan N; Rani S; O'Driscoll L; Crown J; Duffy MJ Cancer Biol Ther; 2013 Jun; 14(6):537-45. PubMed ID: 23760496 [TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
3. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161 [TBL] [Abstract][Full Text] [Related]
4. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors are not all equal. Dent P Cancer Biol Ther; 2013 Oct; 14(10):873-4. PubMed ID: 24025256 [TBL] [Abstract][Full Text] [Related]
6. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib. Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327 [TBL] [Abstract][Full Text] [Related]
7. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells. Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224 [TBL] [Abstract][Full Text] [Related]
8. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349 [TBL] [Abstract][Full Text] [Related]
9. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Patel AG; De Lorenzo SB; Flatten KS; Poirier GG; Kaufmann SH Clin Cancer Res; 2012 Mar; 18(6):1655-62. PubMed ID: 22291137 [TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
11. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710 [TBL] [Abstract][Full Text] [Related]
12. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer. Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663 [TBL] [Abstract][Full Text] [Related]
13. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502 [TBL] [Abstract][Full Text] [Related]
14. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer. Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164 [TBL] [Abstract][Full Text] [Related]
15. BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy. Sriramulu S; Thoidingjam S; Siddiqui F; Brown SL; Movsas B; Walker E; Nyati S Biomolecules; 2024 May; 14(6):. PubMed ID: 38927028 [TBL] [Abstract][Full Text] [Related]
16. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Daemen A; Wolf DM; Korkola JE; Griffith OL; Frankum JR; Brough R; Jakkula LR; Wang NJ; Natrajan R; Reis-Filho JS; Lord CJ; Ashworth A; Spellman PT; Gray JW; van't Veer LJ Breast Cancer Res Treat; 2012 Sep; 135(2):505-17. PubMed ID: 22875744 [TBL] [Abstract][Full Text] [Related]
17. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Han C; McNamara B; Bellone S; Harold J; Manara P; Hartwich TMP; Mutlu L; Yang-Hartwich Y; Zipponi M; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD Gynecol Oncol; 2023 Mar; 170():172-178. PubMed ID: 36706643 [TBL] [Abstract][Full Text] [Related]
18. Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells. Malka MM; Eberle J; Niedermayer K; Zlotos DP; Wiesmüller L Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356606 [TBL] [Abstract][Full Text] [Related]
19. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187 [TBL] [Abstract][Full Text] [Related]
20. BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression. Li Y; Wang Y; Zhang W; Wang X; Chen L; Wang S Sci Rep; 2021 Feb; 11(1):4774. PubMed ID: 33637776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]